Home Blog of Signal Transduction Cell Cycle Chk

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Chk

Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer

270 views | Jan 21 2024

Identifying DNA repair deficiencies in lung cancer through the FATSI method may pave the way for tailored treatments targeting specific vulnerabilities, potentially revolutionizing therapeutic strategies for a subset of patients. [Read the Full Post]

HDAC11 mediates the ubiquitin-dependent degradation of p53 and inhibits the anti-leukemia effect of PD0166285

260 views | Nov 23 2023

The study demonstrates the potential of the WEE1 inhibitor PD0166285 as a promising chemotherapeutic drug for acute myeloid leukemia, highlighting the negative correlation between HDAC11 expression and AML patient survival, and revealing HDAC11's impact on p53 stability and MAPK pathway phosphorylation levels. [Read the Full Post]

Identification of inhibitors for the transmembrane Trypanosoma cruzi eIF2α kinase relevant for parasite proliferation

179 views | Nov 08 2023

The study demonstrates that the TcK2 protein kinase in Trypanosoma cruzi plays a crucial role in parasite proliferation and differentiation, and Dasatinib shows potential as a lead inhibitor for developing therapeutics targeting TcK2 in the treatment of Chagas disease. [Read the Full Post]

Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer

316 views | Oct 17 2023

Targeting DNA damage response and repair pathways with inhibitors of cell-cycle checkpoint proteins represents a promising strategy to overcome radioresistance and improve the sensitivity of colorectal cancer cells to radiotherapy, with potential for combination therapies involving immunotherapy. [Read the Full Post]

Synergistic targeting of CHK1 and mTOR in MYC-driven tumors

422 views | Oct 11 2023

Simultaneous targeting of CHK1 and mTOR emerges as a novel and potent co-treatment modality for MYC-mediated tumors, impairing cell viability and inducing synergistic lethality in vitro and impeding tumor progression in vivo. [Read the Full Post]

Selective inhibition of ATM-dependent double-strand break repair and checkpoint control synergistically enhances the efficacy of ATR inhibitors

727 views | Sep 17 2023

Inhibition of ATR kinase and simultaneous suppression of ATM kinase synergistically enhance cancer cell death and show promise as a novel combination approach for cancer therapy. [Read the Full Post]

Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy

596 views | Sep 17 2023

VX-970 (berzosertib or M6620) is a promising small-molecule ATR inhibitor that shows potential as an effective anticancer drug, both as monotherapy and in combination with chemotherapy or radiotherapy strategies, based on preclinical data and ongoing phase I/II clinical trials. [Read the Full Post]

Checkpoint kinase‑1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologous recombination DNA damage repair

230 views | Jul 25 2023

In summary, the study demonstrates that silencing CHK1 or inhibiting its activity, in combination with chemotherapy, shows promise as an effective strategy for enhancing the cytotoxic effects and overcoming chemotherapeutic resistance in chronic myeloid leukemia (CML). [Read the Full Post]

Chk1 and the Host Cell DNA Damage Response as a Potential Antiviral Target in BK Polyomavirus Infection

0 views | Nov 07 2022

Lydia E Hainley et al. thought that Chk1 inhibitors that were found to be safe and effective in clinical trials for cancer should be evaluated for antiviral activity against BKPyV. [Read the Full Post]

H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models

0 views | Nov 05 2022

Santiago Haase et al. demonstrated that DDRi and STING agonists in combination with RT induce immune-mediated therapeutic efficacy in G34-mutant pHGG. [Read the Full Post]